静脉tPA(组织型纤溶酶原激活剂)与急性缺血性卒中有利的静脉流出特征相关
这项回顾性多中心队列研究纳入717例因大血管闭塞接受血管内取栓分诊的急性缺血性卒中患者,比较tPA+组365例与tPA-组352例的静脉流出(VO)特征。tPA+组185例(51%)与tPA-组100例(28%)出现有利VO(P<0.001);多变量回归显示tPA给药为有利VO特征的强独立预测因子(OR 2.6,95%CI 1.7-4.0;P<0.001)。
要点
- tPA+组有利VO比例51%(185例)高于tPA-组28%(100例),P<0.001。
- 多变量分析中tPA给药与有利VO独立相关(OR 2.6,95%CI 1.7-4.0;P<0.001)。
- tPA+组心房颤动比例35%(128例)低于tPA-组44%(156例),P=0.012。
核心结论
- 在大血管闭塞所致急性缺血性卒中接受取栓分诊的患者中,tPA给药与有利VO特征的存在强相关。
研究设计与样本
- 回顾性多中心队列研究,纳入717例因大血管闭塞所致急性缺血性卒中接受血管内取栓分诊的患者。
- 所有患者在EVT前接受CT、CTA和CT灌注检查。
主要发现
- tPA+组365例中185例(51%)出现有利VO,tPA-组352例中100例(28%)出现有利VO(P<0.001)。
- tPA+组心房颤动128例(35%)少于tPA-组156例(44%),P=0.012。
- tPA+组卒中前抗凝/抗血小板治疗130例(36%)少于tPA-组178例(52%),P<0.001。
- 控制有利软脑膜动脉CTA侧支、CT灌注组织水平侧支、年龄、就诊时NIHSS评分、抗血小板/抗凝治疗、心房颤动史及症状发作至影像时间后,tPA给药为有利VO特征的强独立预测因子(OR 2.6,95%CI 1.7-4.0;P<0.001)。
关键数值与推荐
- VO特征依据CTA上Labbé静脉、蝶顶窦和浅大脑中静脉的显影程度评分:0分不显影,1分中等显影,2分完全显影。
- 软脑膜动脉侧支在CTA上分级,组织水平侧支用CT灌注的灌注不足强度比评估。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Intravenous tPA (tissue-type plasminogen activator) is often administered before endovascular thrombectomy (EVT). Recent studies have questioned whether tPA is necessary given the high rates of arterial recanalization achieved by EVT, but whether tPA impacts venous outflow (VO) is unknown. We investigated whether tPA improves VO profiles on baseline computed tomography (CT) angiography (CTA) images before EVT. METHODS: Retrospective multicenter cohort study of patients with acute ischemic stroke due to large vessel occlusion undergoing EVT triage. Included patients underwent CT, CTA, and CT perfusion before EVT. VO profiles were determined by opacification of the vein of Labbé, sphenoparietal sinus, and superficial middle cerebral vein on CTA as 0, not visible; 1, moderate opacification; and 2, full. Pial arterial collaterals were graded on CTA, and tissue-level collaterals were assessed on CT perfusion using the hypoperfusion intensity ratio. Clinical and demographic data were determined from the electronic medical record. Using multivariable regression analysis, we determined the correlation between tPA administration and favorable VO profiles. RESULTS: Seven hundred seventeen patients met inclusion criteria. Three hundred sixty-five patients received tPA (tPA+), while 352 patients were not treated with tPA (tPA-). Fewer tPA+ patients had atrial fibrillation (n=128 [35%] versus n=156 [44%]; P=0.012) and anticoagulants/antiplatelet treatment before acute ischemic stroke due to large vessel occlusion onset (n=130 [36%] versus n=178 [52%]; P<0.001) compared with tPA- patients. One hundred eighty-five patients (51%) in the tPA+ and 100 patients (28%) in the tPA- group exhibited favorable VO (P<0.001). Multivariable regression analysis showed that tPA administration was a strong independent predictor of favorable VO profiles (OR, 2.6 [95% CI, 1.7-4.0]; P<0.001) after control for favorable pial arterial CTA collaterals, favorable tissue-level collaterals on CT perfusion, age, presentation National Institutes of Health Stroke Scale, antiplatelet/anticoagulant treatment, history of atrial fibrillation and time from symptom onset to imaging. CONCLUSIONS: In patients with acute ischemic stroke due to large vessel occlusion undergoing thrombectomy triage, tPA administration was strongly associated with the presence of favorable VO profiles.
引用
- Faizy TD, Mlynash M, Marks MP, et al. Intravenous tPA (Tissue-Type Plasminogen Activator) Correlates With Favorable Venous Outflow Profiles in Acute Ischemic Stroke. Stroke. 2022. PMID: 35735008. doi:10.1161/STROKEAHA.122.038560
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。